- Home
- BXC vs AGMB Comparison
BXC vs AGMB Comparison
Compare BXC & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXC | AGMB |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | Belgium |
| Employees | 1700 | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.5M | 576.2M |
| IPO Year | 2004 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BXC | AGMB |
|---|---|---|
| Price | $60.76 | $7.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $88.33 | $37.67 |
| AVG Volume (30 Days) | ★ 148.2K | 101.1K |
| Earning Date | 11-03-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $137.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.78 | $6.52 |
| 52 Week High | $93.80 | $17.82 |
Technical Indicators
Market Signals| Indicator | BXC | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 43.83 |
| Support Level | $47.84 | N/A |
| Resistance Level | $62.94 | $9.55 |
| Average True Range (ATR) | 5.15 | 0.82 |
| MACD | -1.24 | 0.03 |
| Stochastic Oscillator | 2.92 | 52.01 |
Price Performance
Historical ComparisonAbout BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh, and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.